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platelet production, resulting in low platelet counts (thrombocytopenia). 
Romiplostim has shown efficacy in increasing platelet counts. The objective  
of this study was to conduct meta-analysis and present total evidence  
for Romiplostim for treatment of ITP. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs) evaluating Romiplostim for the 
treatment of ITP. We included RCTs that compared romiplostim versus placebo 
for management of ITP, had a treatment duration of at least 24 weeks,  
were doubleblind (patients and investigators blinded) and reported data  
on platelet response. A systematic literature search for Etanercept trials  
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar,  
and Cochrane. Data was collected for the study size, interventions, year, and the 
two outcomes overall and durable platelet response rate. For meta-analysis, 
random effects and fixed effects models were used to obtain cumulative 
statistics. RESULTS: Two RCTs with a total of 125 patients were identified.  
The pooled response rates for Romiplostim for overall platelet response  
rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% 
(95% CI 26%-71%). The pooled response rates for placebo for overall platelet 
response rate were 7% (95% CI 0%-15%), and for durable platelet response rate 
were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative 
relative risk with Romiplostim versus placebo was 0.09 (95% CI 4%-14%). For 
durable platelet response rate, the cumulative relative risk with Romiplostim 
versus placebo was 0.03 (95% CI 0%-6%). CONCLUSIONS: Meta-analysis shows 
Romiplostim offers patients with ITP an effective therapeutic option for 
increasing platelet counts.  
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PHARMACOECONOMICAL EVALUATION OF RITUXIMAB FOR NON-HODGKIN'S 
LYMPHOMA: A SYSTEMATIC REVIEW  
SUN Y 
Peking University, Beijing, China  
OBJECTIVES: Rituximab maintenance therapy is associated with significant 
improvement in progression-free and overall survival in patients with NHL. 
However, treatment with rituximab causes considerable costs for health care 
systems. This article provides an overview of Pharmacoeconomical evaluations 
of rituximab and appraises their methodological quality. METHODS: A 
systematic literature search of cost-effectiveness studies on rituximab was 
carried out in several databases, such as PubMed, HTA databases and so on. 
Based on specified inclusion and exclusion criteria, cost-effectiveness studies 
were identified that compared standard chemotherapy with standard 
chemotherapy plus rituximab in patients with a subtype of NHL, including 
diffuse large B-cell lymphoma. The methodological quality of the studies was 
assessed using a quality checklist. RESULTS: The included researches are from 
several countries: the US, UK, Finland, France, Italy and so on. The average ICER 
in the UK is about USD$16318/QALY (GBP10173/QALY), $17688/QALY 
(EUR13275/QALY) in the EU and USD$22461/QALY in the US. All economic 
evaluations reported incremental cost-effectiveness ratios (ICERs) for the add-on 
therapy with rituximab that were below the country-specific thresholds, 
GBP20000~30000/QALY in the UK, EUR30000 ~50000/QALY in the EU and 
USD100000/QALY in the US. CONCLUSIONS: Although the cost of rituximab-
related treatments are relatively higher, they are still cost-effective therapy 
based on the country-specific thresholds.  
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OBJECTIVES: To conduct a systematic review and comparison of pharmacologic 
therapies for treating neuropathic pain (NeP) associated with stroke, HIV, 
trauma, and multiple sclerosis (MS). METHODS: Systematic searches of 
electronic literature databases were conducted to identify randomized, blinded, 
controlled trials of NeP associated with stroke, HIV, trauma, and MS published 
through June 2011. Identified references were screened for inclusion by two 
independent reviewers. Data extracted and evaluated from each study included 
pain severity (11-point numeric rating scale [NRS] or visual analog scale [VAS]), 
proportion of patients achieving 30% and 50% reductions in pain, adverse events 
(AEs), and discontinuations. RESULTS: Eighteen studies met inclusion/exclusion 
criteria. Sample sizes were generally small (11-145 patients) except for 2 HIV, 1 
trauma, and 1 post-stroke pain containing 219-307 patients. Two of the four 
stroke studies presenting mean treatment effects over that of placebo reported 
reductions of -0.2 to -0.3 on NRS for pregabalin, amitriptyline and 
carbamazepine. Of the nine HIV studies, topical capsaicin gave the largest 
treatment effect on the NRS (-2.5). NGX-4010 was the only treatment showing 
higher relative benefit for 30% or 50% pain reduction compared with placebo. Of 
three trauma studies, pregabalin, mexiletine, and gabapentin showed NRS or 
VAS mean pain reductions numerically superior to placebo, although some 
effects were very small. Only pregabalin provided a significant relative benefit of 
30% pain reduction. Two MS studies (<30 patients each) showed mixed efficacy 
for lamotrigine (+0.8 NRS) and levetiracetam (-33.1 VAS). Most studies had 
insufficient data to compare AE risk. Available discontinuation data showed 
similar rates between treatments and placebo. CONCLUSIONS: Studies of NeP 
treatment associated with stroke, HIV, trauma, and MS were few, frequently 
small, and lacked measurements of uncertainty necessary to perform adequate 
comparisons. More and better evaluation of NeP treatment in patients with these 
conditions are needed.  
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OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic connective tissue 
disorder in which the immune system attacks healthy tissue and cells, leading to 
symptoms such as fatigue, muscle pain, and a “butterfly” rash on the nose and 
cheeks. The study objective was to conduct a systematic review and meta-
analysis of new and pipeline B-cell therapies for SLE treatment. METHODS: A 
systematic literature review was conducted in MEDLINE databases from January 
1, 2007 to December 26, 2012 that evaluated primary literature of phase 2 or 
phase 3 studies of B-cell therapies (belimumab, atacicept, epratuzumab, 
tabalumab, blisibimod) in SLE. The search was limited to human studies 
published in English. Descriptive and outcomes data were extracted to assess the 
feasibility of conducting a meta-analysis of comparable endpoints among the 
selected studies. Meta-analysis is in progress. RESULTS: Based on 90 articles 
returned from search terms, 6 articles met search criteria. The 84 excluded 
articles comprised: 29 review articles, 11 phase 1 trials, 14 non-SLE disease 
states, 6 non-human trials, and 24 biologic components of B-cell inhibition. Final 
search results provided 2 studies of pooled analyses of phase 3 belimumab trials. 
Two studies were randomized phase 3 trials of belimumab and 2 studies were 
randomized phase 2 trials of belimumab. The remaining 2 studies were pooled 
sub-analyses of the aforementioned phase 3 trials. Using the criteria set forth by 
Jadad, et al, 4 articles were graded to be excellent (≥66% criteria met), and 2 
articles were rated as poor (<66% criteria met). Feasibility analyses resulted in 2 
studies wherein a meta-analysis could be conducted for SRI response rate, PGA 
score, SF-36 score, and steroid-sparing activity of belimumab vs placebo. 
CONCLUSIONS: Current published literature of phase 2 and phase 3 trials in  
B-cell new product entrants is limited to belimumab for the treatment of SLE.  
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TRENDS IN OBESITY AWARENESS, WEIGHT CONTROL AND WEIGHT CONTROL 
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OBJECTIVES: To examine trends in weight control and weight control practices 
among obese persons aged 20 years and older in the U.S from 1999-2010. 
METHODS: Data were analyzed from National Health and Nutrition Examination 
Survey (NHANES) 1999-2010, representing the civilian, noninstitutionalized 
population of the U.S. Obesity was defined as a BMI greater than 30 kg/m2. 
Weight control and weight control practices were based on self-report. All survey 
periods were age-adjusted to the year 2000 US population. RESULTS: Obesity 
awareness decreased from 92.0% (95% CI, 89.9-94.1%) in 1999-2000 to 90.3% (95% 
CI, 89.0-91.6%) in 2009-2010 (P<0.001), it remained stable among men, but 
decreased significantly among women (P=0.01). The percentage of obese persons 
tried to control their weight in the previous 12 months remained stable over 
time, across age, race, and sex groups, including those who tried to lose weight 
(58.6% in 1999-2000 vs. 59.2% in 2009-2010) and those who tried to maintain 
weight (9.1% in 1999-2000 vs. 8.8% in 2009-2010). Among obese persons who tried 
to control their weight, proportion of those who changed their dietary habit 
increased from 48.7% (95%CI, 43.9-53.5%) in 1999-2000 to 63.3% (95%CI, 59.2-
67.4%) in 2009-2010 (P<0.001), proportion of those who increased physical 
activities level increased from 32.6% (95%CI, 28.6-36.6%) in 1999-2000 to 39.3% 
(95%CI, 35.4-43.1%) in 2009-2010 (P=0.05), but proportion of those who combined 
diet control with the higher levels of physical activity did not change 
significantly over time (27.0% in 1999-2000 vs. 33.7% in 2009-2010; P=0.32). 
CONCLUSIONS: Although sixty-eight percent of obese adults reported pursuing 
weight control in NHANES 2009-2010, most of them did not follow 
recommendations for combined caloric restriction with higher levels of physical 
activity.  
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OBJECTIVES: To describe the prevalence of acupuncture and chiropractic use 
among commercially insured patients with rheumatoid arthritis, osteoarthritis, 
neuropathic pain, diabetic peripheral neuropathy or general joint or back pain. 
METHODS: Patients who used acupuncture or chiropractic during 2009-2011 
were identified in the Truven Health Analytics MartketScan Commercial Claims 
and Encounters and Medicare Supplemental Databases. The disease subgroups 
were identified using ICD-9-CM codes. All analyses were conducted using the 
Truven Health Treatment Pathways research tool. RESULTS: Overall, less than 
one-half percent of patients in the MarketScan Research Databases had an 
acupuncture claim between 2009 and 2011. The average age of an acupuncture 
user was 45.2 (SD=14.3) and more than two-thirds (67.7%) were female. 
Acupuncture use was highest among patients with neuropathic pain (1.41%), 
followed by general joint or back pain (1.23%), osteoarthritis (1.10%), rheumatoid 
arthritis (0.99%), and diabetic peripheral neuropathy (0.65%). By comparison, 
7.1% of patients in the dataset had a chiropractic claim between 2009 and 2011. 
Chiropractic users had an average age of 41.9 (SD=16.5) and 56.7% were female. 
Chiropractic use was most prevalent among patients with general joint or back 
pain (21.0%), followed by neuropathic pain (17.4%), osteoarthritis (13.7%), 
rheumatoid arthritis (10.9%), and diabetic peripheral neuropathy (9.7%). 
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Acupuncture use was nearly six times more common among chiropractic users 
than in the overall population (2.2% vs. 0.37%); similarly, nearly half (42.5%) of 
acupuncture users also had a claim for chiropractic. Over one-in-five patients 
(21.0%) with general joint or back pain used chiropractic, of which 2.65% also 
used acupuncture. CONCLUSIONS: Despite trends suggesting increased use of 
chiropractic and acupuncture, their use remains very low in commercial health 
insurance plans, including patients with inflammation and pain-related 
conditions. While still very low, acupuncture use was more common among 
chiropractic users than in the overall population.  
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OBJECTIVES: To examine the geographic, age and racial variation in the 
prevalence of systemic lupus erythematosus (SLE) in the U.S. veteran population. 
METHODS: Patients diagnosed with SLE (International Classification of Disease 
9thRevision Clinical Modification (ICD-9-CM) diagnosis code 710.0) were included 
in a retrospective study (October 1, 2005 - May 31, 2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Disease prevalence 
was stratified by state, age and race for all the patients, and each category was 
then carefully studied. Descriptive statistics were calculated as means ± 
standard deviation (SD) and percentages to measure the prevalence in the 
sample. RESULTS: A total of 13,257 veterans were diagnosed with SLE in 2011. 
For SLE patients between ages 35 and 54, prevalence was the highest at 0.11%, 
followed by patients age 55 to 64 at 0.07%. Patients age 18-25 and 65+ had SLE 
prevalence of 0.03%, and the median prevalence (0.06%) was observed in patients 
age 26-34. Prevalence by race was also examined: Non-Hispanic Black (0.16%), 
Hispanic (0.07%), Non-Hispanic White (0.05%) and other races (0.04%). 
Geographic variation was examined and the highest SLE prevalence was 
observed in Georgia and Alabama (both 0.11%), followed by Arizona, New 
Hampshire, Maryland, Tennessee, Vermont and Virginia (all 0.08%). 
CONCLUSIONS: There is statistical evidence that middle-aged patients have a 
higher probability to be diagnosed with SLE, and younger and elderly patients 
have a relatively smaller probability. Stratified by race, black, Hispanic and white 
patients were more likely to be diagnosed with SLE compared to other races. 
Statistical results also show that patients living in the Southeastern are of the 
United States had a higher risk of SLE diagnosis.  
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OBJECTIVES: The aim of this study was to evaluate the impact of race on quality 
of anticoagulation control in patients undergoing major orthopedic surgery. 
METHODS: We conducted a retrospective, observational cohort study in an 
inner-city underserved population treated with warfarin thromboprophylaxis 
after total hip replacement (THR) or total knee replacement (TKR), referred to a 
specialized antithrombosis clinic from 1998 to 2009. Significant variables from 
simple linear regression (p < 0.1) were entered in stepwise multivariate logistic 
regression (alpha < 0.05) to evaluate the effect of race on quality of 
anticoagulation control, defined as within-patient proportion of international 
normalized ratio (INR) levels spent in therapeutic range (INR of 2-3 ± 0.2). 
RESULTS: A total of 400 consecutive patients were evaluated. The average age 
was 58.4±12.5, 56% were African-American, and 26% were Hispanic. The average 
length of warfarin therapy was 50±21 days, and the average within-patient 
proportion of INR levels spent in therapeutic range was 39.2±20.5%. African-
Americans (β= -8.59, p < 0.0001) had lower within-patient proportion of INR 
levels spent in therapeutic range compared to non-African-Americans. In 
addition, males (β= -5.17, p = 0.0069), higher warfarin dose (β= -3.13, p <0.0001), 
higher frequency of anticoagulation monitoring visits (β= -1.13, p = 0.0214) and 
non-adherence with warfarin (β= -0.31, p <0.0001) were significantly associated 
with a lower proportion of INR levels in therapeutic range. After controlling for 
age, gender, comorbidities, and significant covariates, the effect of African-
American race remained significant (β= -6.90, p = 0.0001). CONCLUSIONS: In this 
inner-city underserved population treated with warfarin thromboprophylaxis for 
THR and TKR, African-Americans tended to have lower proportion of INR levels 
in therapeutic range than non-African-Americans. Studies are needed to further 
elucidate factors driving substandard anticoagulation control in minority 
patients.  
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OBJECTIVES: Neuropathic pain (NeP) is a pain caused by a lesion or disease of 
the somatosensory nervous system (International Association for the Study of 
Pain – IASP 2011). In many cases NeP is secondary to herpes zoster infection and 
as a complication of diabetes mellitus. This study aimed to assess the budget 
impact of pregabalin in NeP in adult Colombian population. METHODS: A budget 
impact model was developed with a time horizon of 1 year from the social 
perspective (direct and indirect costs included). Cohort contains 155,030 patients 
over 18 years with NeP, according to Colombian prevalence and considers 20% of 
patients have access to medical treatment. Direct costs (drug acquisition, 
medical visits with general practitioners, specialists and emergency visits) and 
indirect costs (disability payments) of managing patients with neuropathic pain 
were estimated from Colombian sources (tariff manuals and pricing rulings). 
Comparators included those locally approved for NeP: pregabalin (150-300 
mg/day) versus duloxetine (60 mg/day). Univariate deterministic and 
probabilistic sensitivity analyses were done. Costs are in 2012 US$. RESULTS: 
Assuming that each comparator had a 100% market share, the average total 
costs of treating NeP patients for 1 year, with the comparators were: pregabalin 
US $132,965,443 (51.7% drug acquisition, 26.4% medical visits and 21.9% indirect 
costs) and duloxetine US $220,883,844 (68.6% drug acquisition, 14.2% medical 
visits and 17.2% indirect costs). Patients taking pregabalin have a lower 
acquisition cost of drugs. CONCLUSIONS: Pregabalin is a favorable alternative for 
the treatment of NeP compared to duloxetine by saving US $567.1 per 
patient/year compared to duloxetine. Colombian stakeholders should consider 
these findings for future decision-making processes.  
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THE ECONOMIC IMPACT OF INCREASED USE OF MULTI-MODAL ANALGESIA 
FOR THE MANAGEMENT OF POST-SURGICAL PAIN IN THE HOSPITAL SETTING  
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OBJECTIVES: Treating post-surgical patients with opioid and non-opioid 
medications simultaneously can be an effective way to treat pain, minimize 
opioid-associated side-effects, and reduce hospital length of stay (LOS). The 
objective of this exercise was to develop a budget impact model to evaluate the 
economic impact of increased use of multi-modal analgesia following orthopedic 
or abdominal/pelvic surgery in the hospital setting. METHODS: A total of 50,648 
unique patient encounters from a 2009-2012 US electronic health record 
database were evaluated. Patients were segmented into 280 cohorts based on 
surgical procedure (40 unique orthopedic and abdominal/pelvic procedures) and 
NSAID risk factors (7 unique risk groups). Median LOS was calculated for each 
cohort and compared based on analgesia received (opioid-only vs. multi-modal). 
Findings were adjusted to fit the general case of a 250-bed hospital with an 80% 
occupancy rate and performing 3,400 total orthopedic and abdominal/pelvic 
surgeries/year. Median per-day hospital stay costs of $400 and $460 per 
orthopedic and abdominal/pelvic procedure, respectively, were applied. 
RESULTS: Current proportions of patients receiving multi-modal, opioid-only, 
and non-opioid-only therapy were 29.9%, 63.0%, and 7.1%, respectively. Multi-
modal therapy was associated with reduced LOS for 45.2% of cohorts, no change 
in LOS for 41.7% of cohorts, and increased LOS for 13.1% of cohorts. Increasing 
the proportion of patients receiving multi-modal therapy resulted in cost 
savings. Shifting 20% of patients from opioid-only to multi-modal therapy 
resulted in estimated annual savings of $71,526, while shifting 40% of patients in 
this manner reduced costs by $141,317. Conversely, shifting all patients treated 
with multi-modal therapy to opioid-only therapy increased annual costs by 
$105,204. CONCLUSIONS: The model supports the hypothesis that multi-modal 
therapy is associated with reduced LOS and reduced health care costs. While 
currently-available NSAIDs may present their own side-effect risks, NSAIDs with 
improved safety may further reduce costs, assuming similar efficacy and LOS 
effects.  
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Zhang M1, Epstein J2, Zhang L3, Chen W3, Zheng W4 
1Baxter Asia Pacific, Shanghai, China, 2Baxter BioScience, Westlake Village, CA, USA, 3Fudan 
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OBJECTIVES: Hemophilia A is a rare, genetic disorder occurring in males and its 
treatment involves infusing clotting factor concentrate (FVIII). Currently, the 
most widely-used FVIII product in China is plasma-derived FVIII. Since plasma-
derived FVIII is sourced from local blood donations, it is associated with an 
increased risk of blood-borne infection. Blood-borne infections can be life-
threatening and have a significant cost on society. The objective of this study 
was to estimate the extra economic burden associated with a potential blood-
borne infection in the hemophilia population of China. METHODS: An outbreak 
of hepatitis C virus (HCV) was used as a real life example of pathogen 
transmission in the Chinese hemophilia population. Decision tree analysis was 
adopted to calculate the expected life-time incremental cost associated with 
treating hemophilia patients infected with HCV. Costs were discounted and 
sensitivity analyses were conducted to test model sensitivity and assumptions. 
RESULTS: Preventing HCV in hemophilia patients is estimated to save an 
approximately 7 years of life per patient. Expected life-time additional treatment 
cost (FVIII cost not included) of a hemophilia patient infected with HCV was 
estimated at 855,341 RMB. Assuming 10% of the registered Chinese hemophilia A 
patients were affected by HCV, preventing HCV infection in these patients would 
have saved an estimated 774 million RMB in total. CONCLUSIONS: This research 
demonstrates the significant potential economic burden of treating hemophilia 
patients infected with a blood-borne pathogen such as HCV, as well as the value 
of utilizing a FVIII product that eliminates the transmission risk of another 
infectious disease similar to the burden associated with HCV.  
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COSTS ASSOCIATED WITH BREAKTHROUGH PAIN IN CANCER PATIENTS: 
FINDINGS FROM THE NATIONAL BREAKTHROUGH PAIN SURVEY  
